Filanesib
A synthetic, small molecule targeting the kinesin spindle protein (KSP) with potential antineoplastic activity. Filanesib specifically inhibits KSP (kinesin-5 or Eg5), resulting in activation of the spindle assembly checkpoint, induction of cell cycle arrest during the mitotic phase, and consequently cell death in tumor cells that are actively dividing. Because KSP is not involved in postmitotic processes, such as neuronal transport, this agent does not cause the peripheral neuropathy that is often associated with tubulin-targeting agents. KSP is an ATP-dependent microtubule motor protein that is essential for the formation of bipolar spindles and the proper segregation of sister chromatids during mitosis. [ ]
Term info
Filanesib
- 1,3,4-Thiadiazole-3(2H)-carboxamide, 2-(3-Aminopropyl)-5-(2,5-difluorophenyl)-N-methoxy-N-methyl-2-phenyl-, (2S)-
- ARRY-520
- ARRY520
- Filanesib
NCIT_C116978, NCIT_C128784, NCIT_C116977, NCIT_C157711, NCIT_C157712
885060-09-3
CTRP
Filanesib
KSP_Inhibitor_ARRY-520
546990
546990
Filanesib
Pharmacologic Substance, Organic Chemical
C2346611
C68937
Term relations
- Mitotic Kinesin Modulator
- Chemical_Or_Drug_Has_Mechanism_Of_Action some Enzyme Inhibition
- Chemical_Or_Drug_Has_Physiologic_Effect some Positive Regulation of Apoptosis
- Chemical_Or_Drug_Affects_Gene_Product some Kinesin-Like Protein KIF11
- Chemical_Or_Drug_Has_Physiologic_Effect some Negative Regulation of Cell Cycle